Detail akcie Aclaris Therap online

Business Summary: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Aclaris Therapeutics Inc revenues decreased 5% to $2.4M. Net loss decreased 40% to $16.9M. Revenues reflect Contract Research segment decrease of 87% to $657K. Lower net loss reflects Therapeutics segment loss decrease of 43% to $12.2M, Corporate segment loss decrease of 26% to $5.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.42 to -$0.24.